188 related articles for article (PubMed ID: 11584187)
1. Orally active heparin and low-molecular-weight heparin.
Pineo GF; Hull RD; Marder VJ
Curr Opin Pulm Med; 2001 Sep; 7(5):344-8. PubMed ID: 11584187
[TBL] [Abstract][Full Text] [Related]
2. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
4. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
5. Oral delivery of heparin: SNAC and related formulations.
Pineo G; Hull R; Marder V
Best Pract Res Clin Haematol; 2004 Mar; 17(1):153-60. PubMed ID: 15171964
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic therapy for the management of thrombosis: unfractionated heparin or low-molecular-weight heparin?
Spyropoulos AC
Clin Cornerstone; 2005; 7(4):39-48. PubMed ID: 16758651
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
[TBL] [Abstract][Full Text] [Related]
8. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
Valiukiene L; Naudziūnas A; Unikauskas A
Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
[TBL] [Abstract][Full Text] [Related]
9. [Heparins and curative treatment of venous thromboembolic disease: meta-analysis].
Mismetti P; Laporte-Simitsidis S; Leizorovicz A; Decousus H
Therapie; 1997; 52(1):47-52. PubMed ID: 9183922
[TBL] [Abstract][Full Text] [Related]
10. Repeated doses of oral and subcutaneous heparins have similar antithrombotic effects in a rat carotid arterial model of thrombosis.
Hiebert LM; Ping T; Wice SM
J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):110-6. PubMed ID: 21512111
[TBL] [Abstract][Full Text] [Related]
11. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
Hiebert LM
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.
Heaton D; Pearce M
Pharmacoeconomics; 1995 Aug; 8(2):91-9. PubMed ID: 10155614
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
Hansen JB; Sandset PM
Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis.
Leizorovicz A
Drugs; 1996; 52 Suppl 7():30-7. PubMed ID: 9042557
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
[TBL] [Abstract][Full Text] [Related]
17. [Evidence-based guidelines for prevention and therapy of venous thromboembolism].
Falciani M; Dilaghi B; Conti AA; Caciolli S; Gensini GF
Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):27-35. PubMed ID: 11253337
[TBL] [Abstract][Full Text] [Related]
18. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.
Samama CM; Vray M; Barré J; Fiessinger JN; Rosencher N; Lecompte T; Potron G; Basile J; Hull R; Desmichels D;
Arch Intern Med; 2002 Oct; 162(19):2191-6. PubMed ID: 12390061
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
Dolovich LR; Ginsberg JS; Douketis JD; Holbrook AM; Cheah G
Arch Intern Med; 2000 Jan; 160(2):181-8. PubMed ID: 10647756
[TBL] [Abstract][Full Text] [Related]
20. New developments in the prevention and treatment of venous thromboembolism.
Pineo GF;
Pharmacotherapy; 2001 Jun; 21(6 Pt 2):51S-55S; discussion 71S-72S. PubMed ID: 11401193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
